Ocular Therapeutix announces topline phase 1 clinical trial results of OTX-CSI

Ocular Therapeutix announces topline phase 1 clinical trial results of OTX-CSI

Source: 
Pharmaceutical Business Review
snippet: 


Ocular Therapeutix, a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced topline Phase 1 clinical trial results of OTX-CSI (cyclosporine intracanalicular insert) for the treatment of dry eye disease (DED).